Abstract 135P
Background
Two classical models have been proposed for the development of colorectal cancer (CRC) from colon epithelial cells, transformation of adenoma and serrated polyps to cancer. However, clinical data showed that there is still a certain amount of CRC is not derived from the above two pathways, forming the theoretical island of CRC pathogenesis. Laterally spreading tumor (LST) is an important precancerous lesion of CRC, while the molecular mechanism of it's carcinogenesis remained unclear.
Methods
We proposed a two-stage cascade mutation hypothesis for LST cancerization. Based on the mRNA data of 25711 samples from 980 healthy donors in the genotype-tissue expression, pan-cancer mRNA-sequencing and survival data.We performed a differential expression and survival analysis of ATM, ANO5, APC, and TP53 in pan-cancer and adjacent normal samples. Furthermore, we validated the noneffective role of PIK3CA signaling pathway in two cell lines, LS174T and SW1116 by constructing three SiRNA (PIK3CA-SiRNA-1, PIK3CA-SiRNA-2, PIK3CA-SiRNA-3), to confirm the vital role of TGFβ and p53 signaling pathway involving in LST cancerization.
Results
The expression profiles of ATM, ANO5, APC and TP53 in normal and pan-cancer samples were significantly downregulated in rectal adenocarcinoma, colon adenocarcinoma, and their joint samples. In contrast, TP53 showed an obviously higher level in all of above samples. ATM, ANO5, APC, and TP53 expression were correlated with the overall survival of colorectal cancer patients. ATM and ANO5, which closely related to the Golgi apparatus fragmentation in LST samples presented a significant changes. The SiRNA interference test showed that the expression level of PIK3CA was not significantly different from the control group.
Conclusions
These findings suggested that early APC mutations induced a Golgi fragmentation event, weakened the expression of wild-type TP53 transcription factor MDM2 and TP73, modulated the stability of mutant TP53, ultimately promoted the carcinogenesis process of the LST. The PI3K signaling pathway is not closely associated with LST carcinogenesis. These observations suggest the existence of a unique and novel pathway for the development of CRC from LST.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China; Gansu Medical College.
Disclosure
The authors have declared no conflicts of interest.
Resources from the same session
152P - Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping
Presenter: Khashayar Roohollahi
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - Discovery of new BRCA1/2 mutations not described in the international breast consortium
Presenter: Wala Ben Kridis
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - Alternative splicing in non-small cell lung cancer evolution
Presenter: Michelle Leung
Session: Cocktail & Poster Display session
Resources:
Abstract
155TiP - Exploring mechanisms of action and resistance to innovative therapeutic drugs: UNLOCK program
Presenter: Julieta Rodriguez
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - Therapeutic potential of B7-H3 targeting in pediatric neuroblastoma
Presenter: Caroline E Nunes-Xavier
Session: Cocktail & Poster Display session
Resources:
Abstract
158P - E-JIB-04: An epigenetic targeted therapy for ovarian cancer with MECOM amplification
Presenter: Ibha Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - The impact of kisspeptin pre-treatment towards temozolomide resistance mechanisms and associated differently expressed proteins (DEPs) in human glioblastoma cells
Presenter: Isra Sati
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - Clinical observation and immune effects of high-intensity focused ultrasound (HIFU) in the treatment of liver metastasis in colorectal cancer
Presenter: Shasha Wang
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - Early phase cancer clinical trials: A viable treatment option for patients?
Presenter: Rhona Dawson
Session: Cocktail & Poster Display session
Resources:
Abstract
162P - Tailoring patient molecular selection for novel anti-MET therapies
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract